[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
The complex pathway between amyloid β and cognition: implications for therapy
For decades, the hypothesis that brain deposition of the amyloid β protein initiates
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …
Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation
Introduction As clinical trials move toward earlier intervention, we sought to redefine the β-
amyloid (Aβ)-PET threshold based on the lowest point in a baseline distribution that robustly …
amyloid (Aβ)-PET threshold based on the lowest point in a baseline distribution that robustly …
Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease
Objective To understand the time course of β-amyloid (Aβ) deposition in the brain, which is
crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD) …
crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD) …
Multitracer model for staging cortical amyloid deposition using PET imaging
Objective To develop and evaluate a model for staging cortical amyloid deposition using
PET with high generalizability. Methods Three thousand twenty-seven individuals (1,763 …
PET with high generalizability. Methods Three thousand twenty-seven individuals (1,763 …
[HTML][HTML] Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer's disease
Introduction: We investigated whether monthly assessments of a computerized cognitive
composite (C3) could aid in the detection of differences in practice effects (PE) in clinically …
composite (C3) could aid in the detection of differences in practice effects (PE) in clinically …
Association of emerging β-amyloid and tau pathology with early cognitive changes in clinically normal older adults
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the
disease process according to emerging signs of β-amyloid (Aβ) and tau pathology. If early …
disease process according to emerging signs of β-amyloid (Aβ) and tau pathology. If early …
Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Objective To examine the feasibility of using cross-sectional PET to identify cognitive
decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults. Methods …
decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults. Methods …
Soluble amyloid-β consumption in Alzheimer's disease
AJ Espay, A Sturchio, LS Schneider… - Journal of Alzheimer's …, 2021 - content.iospress.com
Brain proteins function in their soluble, native conformation and cease to function when
transformed into insoluble aggregates, also known as amyloids. Biophysically, the soluble-to …
transformed into insoluble aggregates, also known as amyloids. Biophysically, the soluble-to …
[HTML][HTML] Decoding the heterogeneity of Alzheimer's disease diagnosis and progression using multilayer networks
B Avelar-Pereira, ME Belloy, R O'Hara… - Molecular …, 2023 - nature.com
Alzheimer's disease (AD) is a multifactorial and heterogeneous disorder, which makes early
detection a challenge. Studies have attempted to combine biomarkers to improve AD …
detection a challenge. Studies have attempted to combine biomarkers to improve AD …